EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube

A qualitative study of the perspectives of myeloma patients and health care professionals on Minimal Residual Disease (MRD) status as an endpoint for Multiple Myeloma in clinical trials and in treatment decision making

 

Project Launch: April 2022

 

The study aims to gain a deeper understanding of the patient experience and perspective of using minimal residual disease (MRD) status both in clinical trials as a primary endpoint and in health technology and regulatory assessments, and as part of treatment decision making.

 

The broad research questions/aims of the study are to understand:

 

  • Are patients aware of and educated on MRD?
  • What is their perspective on its importance?
  • Role of MRD in regulatory and health technology assessment decisions?
  • Impact on treatment decisions from clinicians and health care professionals
  • Perspectives of patients and health care professionals from different European countries
  • Impact on emotional wellbeing of knowing MRD status
  • What are the challenges around MRD testing?

 

The outputs of this project will advance and expand our knowledge of patients’ and clinicians’ perspectives of MRD, which will inform future research and highlight needs for educational related to this topic.

 

This project will be managed and conducted by MPE.

Patient focus groups will be held on September 7, 2022.

 

Recruitment status: Recruiting 

 

If you would like to participate in this research, please fill out the form below.

If you have any questions, please email research@mpeurope.org, and we will be in touch soon.

 

  •  

  •  

  •  

  •  

  •  

    1. I confirm that I have read and understood the information above. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. (All questions can be sent to research@mpeurope.org).

    2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason.

    3. I understand that my participation in this focus group will be confidential.

    4. I understand that anonymised data may be shared publicly.

    5. I understand that if some of my views are quoted in a report or otherwise published, this will be done anonymously unless I consent to be identified.

    6. I understand that my views will be video recorded for the purpose of the focus group and made available only to the MPE staff and a contracted transcriber preparing the report.

    7. I understand that MPE cannot guarantee the disclosure information shared in this focus group discussion by other participants.

    8. I agree to take part in the focus group.